Oncodesign Services SA, a France-based contract research organisation, has appointed Aidan Synnott as chief executive officer to help strengthen its position in drug discovery. Dr Synnott brings more than 20 years of experience in biomedical research and was most recently corporate vice president of global discovery services at Charles River Laboratories. His appointment coincides with the appointment of Werner Lanthaler, former CEO of Evotec SE, as chairman of Oncodesign Services’ board. Dr Synnott, who has a doctorate in bioengineering from the Tokyo Institute of Technology, Japan, will be based in France and oversee the company’s operations in France and the Netherlands. Oncodesign Services acquired ZoBio, a Dutch CRO, in early 2024 and has expanded recently into molecular radiotherapy and protein sciences.
Oncodesign Services announced the appointments on 31 March 2025.
Copyright 2025 Evernow Publishing Ltd.